Skip to main content

Table 1 Baseline characteristics overall and by gender

From: Dynamics of cinacalcet use and biochemical control in hemodialysis patients: a retrospective New-user cohort design

Characteristica

Total

Female

Male

Demographics

 Patients, N

17,763

8,764

8,999

 Age, mean (SD), yearsb

56.7 (14.5)

59.1 (14.8)

54.4 (13.9)

 Time on dialysis, mean (SD), yearsb

4.5 (4.3)

4.4 (4.1)

4.7 (4.4)

 Race, N (%)

   

  White

7,242 (40.8)

3,436 (39.2)

3,806 (42.3)

  African American

9,555 (53.8)

4,856 (55.4)

4,699 (52.2)

  Other Race

966 (5.4)

472 (5.4)

494 (5.5)

 Cause of ESRD, N (%)

   

  Diabetes

7,629 (42.9)

4,233 (48.3)

3,396 (37.7)

  Hypertension

5,612 (31.6)

2,458 (28.0)

3,154 (35.0)

  Glomerulonephritis

2,236 (12.6)

1,067 (12.2)

1,169 (13.0)

  Other

2,286 (12.9)

1,006 (11.5)

1,280 (14.2)

 Body Mass Index, mean (SD), kg/m2

28.0 (7.3)

28.7 (7.8)

27.4 (6.7)

Financial Considerations

 Medicaid, N (%)

12,206 (68.7)

6,351 (72.5)

5,855 (65.1)

 Low-income subsidy, N (%)

14,906 (83.9)

7,515 (85.7)

7,391 (82.1)

 Concomitant medications, N (%)c

4.7 (3.6)

5.1 (3.7)

4.4 (3.5)

Biochemical Values

 Albumin, mean (SD), g/dLd

3.9 (0.4)

3.8 (0.4)

4.0 (0.4)

 Calcium, mean (SD), mg/dLd

9.4 (0.7)

9.4 (0.7)

9.4 (0.7)

 Phosphorus, mean (SD), mg/dLd

5.9 (1.7)

5.8 (1.7)

6.0 (1.7)

 Parathyroid hormone, mean (SD), pg/mLd

642 (519)

640 (519)

644 (520)

Comorbidities

 Congestive heart failure, N (%)

4,823 (27.2)

2,592 (29.6)

2,231 (24.8)

 Coronary artery disease/atherosclerosis, N (%)

4,703 (26.5)

2,434 (27.8)

2,269 (25.2)

 Cerebrovascular disease, N (%)

1,891 (10.6)

1,087 (12.4)

804 (8.9)

 Hypertension, N (%)

12,393 (69.8)

6,481 (74.0)

5,912 (65.7)

 Peripheral vascular disease, N (%)

2,352 (13.2)

1,208 (13.8)

1,144 (12.7)

 Hyperlipidemia, N (%)

4,658 (26.2)

2,519 (28.7)

2,139 (23.8)

 Chronic obstructive pulmonary disease or asthma, N (%)

2,727 (15.4)

1,530 (17.5)

1,197 (13.3)

 Diabetes, N (%)

10,052 (56.6)

5,491 (62.7)

4,561 (50.7)

Dialysis Care

 Phosphorus binder drug, N (%)e

14,135 (79.6)

7,037 (80.3)

7,098 (78.9)

 Catheter access, N (%)

3,351 (18.9)

1,994 (22.8)

1,357 (15.1)

 Mean intravenous vitamin D dosage, micrograms (SD)f

12.5 (10.3)

11.9 (9.9)

13.1 (10.7)

  1. Note: Conversion factors for units: Calcium in mg/dL to mmol/L, x0.2495; phosphorus in mg/dL to mmol/L, x0.3229
  2. aCharacteristics were identified using information from Medicare Part A or B claims. A characteristic was considered present if at least one inpatient, home health, or skilled nursing facility claim, or at least two outpatient or physician/supplier claims separated by at least 7 days, were identified during the 6-month baseline period. Additional information concerning covariates can be found in Additional file 1: Table S3
  3. bAge and time on dialysis are at the time of cinacalcet initiation
  4. cConcomitant medications are the number of concomitant medications at the time of cinacalcet initiation
  5. dLaboratory values were those most proximal to the index date during the baseline period
  6. ePhosphate binders included in the analysis: Sevelamer hydrochloride, sevelamer carbonate, lanthanum carbonate, and calcium acetate
  7. fMean intravenous vitamin D dose per person in the last month of the baseline period. Paricalcitol and doxercalciferol doses were converted to calcitriol-equivalent doses according to the following conversion ratios: 4.6: 1 for paricalcitol: calcitriol and 3.1: 1 for doxercalciferol: calcitriol
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us